Abstract Number: 2489 • 2014 ACR/ARHP Annual Meeting
Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) decreases in mean peripheral neutrophil count were…Abstract Number: 1463 • 2014 ACR/ARHP Annual Meeting
Dickkopf-1 Perpetuated Synovial Fibroblast Activation and Synovial Angiogenesis in Rheumatoid Arthritis
Background/Purpose . Dkk-1, a master regulator of joint remodeling, is elevated and leads to bone resorption in patients with RA. This study aimed to investigate…Abstract Number: 493 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib Following Inadequate Response to Nonbiologic DMARD or Biologic DMARD
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the efficacy and safety of tofacitinib 5…Abstract Number: 2488 • 2014 ACR/ARHP Annual Meeting
Relationship Between Different Clinical Measurements and Patient-Reported Outcomes
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the relationship between clinical measures and patient-reported…Abstract Number: 1478 • 2014 ACR/ARHP Annual Meeting
Pharmacokinetics, Bioavailability and Safety of a Modified-Release Once-Daily Formulation of Tofacitinib in Healthy Volunteers
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The efficacy and safety of an immediate-release (IR) formulation…Abstract Number: 487 • 2014 ACR/ARHP Annual Meeting
Assessment of Lipid Changes in Patients with Early Rheumatoid Arthritis Treated with Tofacitinib or Methotrexate over 24 Months
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) increases in mean low-density lipoprotein cholesterol (LDL-C) and…Abstract Number: 2487 • 2014 ACR/ARHP Annual Meeting
Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we describe health care resource utilization (HCRU) and work…Abstract Number: 1462 • 2014 ACR/ARHP Annual Meeting
Cadherin-11 mRNA Expression in the Peripheral Blood of Rheumatoid Arthritis Patients As a Marker of Active Polyarthritis
Background/Purpose: Human rheumatoid arthritis synovial fibroblasts (RASF) implanted subcutaneously in immunodeficient mice trans-migrate through the vasculature and drive the progression from oligo- to poly-articular disease.…Abstract Number: 461 • 2014 ACR/ARHP Annual Meeting
Comprehensive Summary of the Efficacy and Safety of Tofacitinib 5mg Twice Daily in Patients with Rheumatoid Arthritis and an Inadequate Response to Disease-Modifying Antirheumatic Drugs
Background/Purpose: Tofacitinib has been approved in the US and other countries at the recommended dose 5 mg BID in patients (pts) with rheumatoid arthritis (RA) and…Abstract Number: 2480 • 2014 ACR/ARHP Annual Meeting
Is there a Difference in the Effectiveness in the Treatment of Rheumatoid Arthritis with Rituximab when Using a Dose of 1 or 2 Grams per Cycle? a Systematic Review
Background/Purpose: Since the description of the efficacy of rituximab (RTX) in treating patients with rheumatoid arthritis (RA), the use of this drug has been extended.…Abstract Number: 1196 • 2014 ACR/ARHP Annual Meeting
Inflammation Develops in a Toll-like Receptor 9-Independent Manner in Experimental Arthritis and Rheumatoid Arthritis
Background/Purpose Rheumatoid arthritis (RA) is an inflammatory disease of unknown etiology. Toll-like receptor (TLR) 9 recognizes pathogen-derived DNA and even self DNA under certain circumstances.…Abstract Number: 460 • 2014 ACR/ARHP Annual Meeting
Analysis of Non-Melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Program
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The incidence of non-melanoma skin cancer (NMSC) in the tofacitinib…Abstract Number: 2455 • 2014 ACR/ARHP Annual Meeting
IL-6 Proximal Promoter SNP rs18000795 Genotype Strongly Correlates with Synovial Fibroblast IL-6 Expression
Background/Purpose Interleukin (IL)-6 is an important driver of rheumatoid arthritis (RA) pathology, and synovial fibroblasts are a major source of IL-6 in the RA synovium. …Abstract Number: 1150 • 2014 ACR/ARHP Annual Meeting
Marked Differences in Euro-Qol-5-Dimensions Preference Sets Based on Hypothetical or Experience Based Valuation
Background/Purpose: Health related quality of life (HRQoL) can be expressed as utility, a value anchored at 0 (death) and 1 (perfect health, forming the basis…Abstract Number: 471 • 2014 ACR/ARHP Annual Meeting
Improving of Safety in Treatment with Biologics during First Seven-Years Experiences; Long-Term Results from Observational Cohort Study of Clinical Practice Using Multicenter Registry in Japan
Background/Purpose: Many evidences including clinical trials of biologics lead us earlier and more aggressive treatment strategy for patients with rheumatoid arthritis (RA). It is stated…
- « Previous Page
- 1
- …
- 176
- 177
- 178
- 179
- 180
- …
- 188
- Next Page »